References
- Long MW, Snider DE Jr, Farer LS. U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis. Am Rev Respir Dis 1979;119:879–894.
- Woo J, Chan C, Chan R, Cheung W, Or K, Chan K. Correlation between steady-state plasma concentration of antituberculous drugs and age, inclusion of rifampicin in the treatment regimen, adverse drug reactions and other clinical parameters. J Med 1995;26:279–294.
- Sankar R, Sharda N, Singh S. Behavior of decomposition of rifampicin in the presence of isoniazid in the pH range 1-3. Drug Dev Ind Pharm 2003;29:733–738.
- Henwood SQ, de Villiers MM, Liebenberg W, Lötter AP. Solubility and dissolution properties of generic rifampicin raw materials. Drug Dev Ind Pharm 2000;26:403–408.
- Cavenaghi R. Rifampicin raw material characteristics and their effect on bioavailability. Bull Int Union Tuberc Lung Dis 1989;64:36–7; 40.
- Boman G, Lundgren P, Stjernström G. Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: adsorption of rifampicin by an excipient, bentonite. Eur J Clin Pharmacol 1975;8:293–299.
- Singh S, Mariappan TT, Shankar R, Sarda N, Singh B. A critical review of the probable reasons for the poor variable bioavailability of rifampicin from anti-tubercular fixed-dose combination (FDC) products, and the likely solutions to the problem. Int J Pharm 2001;228:5–17.
- Agrawal S, Panchagnula R. Implication of biopharmaceutics and pharmacokinetics of rifampicin in variable bioavailability from solid oral dosage forms. Biopharm Drug Dispos 2005;26:321–334.
- Becker C, Dressman JB, Amidon GL, Junginger HE, Kopp S, Midha KK et al.; International Pharmaceutical Federation, Groupe BCS. Biowaiver monographs for immediate release solid oral dosage forms: isoniazid. J Pharm Sci 2007;96:522–531.
- Graff J, Brinch K, Madsen JL. Gastrointestinal mean transit times in young and middle-aged healthy subjects. Clin Physiol 2001;21:253–259.
- Shishoo CJ, Shah SA, Rathod IS, Savale SS, Vora MJ. Impaired bioavailability of rifampicin in presence of isoniazid from fixed dose combination (FDC) formulation. Int J Pharm 2001;228:53–67.
- Avachat AM, Bhise SB. Tailored release drug delivery system for rifampicin and isoniazid for enhanced bioavailability of rifampicin. Pharm Dev Technol 2011;16:127–136.